SCHEMBL2974249

SCHEMBL2974249

O=C1CCC2CC=C(O)C=C2N1

nearest known ligand 0.32

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 9/20 0.32
DDB1 Q16531 7/20 0.32
IKZF3 Q9UKT9 1/20 0.31
ESR2 Q92731 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12473611 0.79 CRBN (0.32) CRBNDDB1
SCHEMBL9055828 0.72 CRBN (0.37) CRBNDDB1IKZF3ESR2
SCHEMBL68773 0.68 CRBN (0.33) CRBNDDB1IKZF3
SCHEMBL33371399 0.68 CRBN (0.33) CRBNDDB1IKZF3
SCHEMBL7985487 0.67 CRBN (0.33) CRBNDDB1IKZF3
SCHEMBL1995236 0.67 CRBN (0.36) CRBNDDB1IKZF3ESR2
SCHEMBL4804572 0.66 MAPT (0.35) CRBNDDB1IKZF3
SCHEMBL9731788 0.64 MAPT (0.34) CRBNDDB1
SCHEMBL7098448 0.63 CRBN (0.36) CRBNDDB1
SCHEMBL5946816 0.62 DDB1 (0.32) CRBNDDB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7777039-B2 Process for the preparation of aripiprazole ALEMBIC LIMITED (IN) 2010-08-17 US claimed
US-7361756-B2 Method of making 7-(4-bromobutoxy)-3,4-dihydrocarbostyril TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2008-04-22 US claimed
WO-2007113846-A1 A PROCESS FOR THE PREPARATION OF ARIPIPRAZOLE ALEMBIC LIMITED (IN) 2007-10-11 WO claimed
EP-1765782-A1 METHOD OF MAKING 7-(4-BROMOBUTOXY)-3,4-DIHYDROCARBOSTYRIL Teva Pharmaceutical Industries Ltd (IL) 2007-03-28 EP claimed
US-20060258869-A1 Process for the preparation of aripiprazole ALEMBIC LIMITED (IN) 2006-11-16 US claimed
WO-2006001846-A1 METHOD OF MAKING 7-(4-BROMOBUTOXY)-3,4-DIHYDROCARBOSTYRIL TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2006-01-05 WO claimed
US-20050215585-A1 Method of making 7-(4-bromobutoxy)-3,4-dihydrocarbostyril TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2005-09-29 US claimed
US-7777039-B2 Process for the preparation of aripiprazole ALEMBIC LIMITED (IN) 2010-08-17 US disclosed
US-7777039-B2 Process for the preparation of aripiprazole ALEMBIC LIMITED (IN) 2010-08-17 US disclosed
EP-1984352-A1 A NOVEL PROCESS FOR PREPARATION OF ARIPIPRAZOLE AND ITS INTERMEDIATES UNICHEM LABORATORIES LIMITED (IN) 2008-10-29 EP disclosed
US-7361756-B2 Method of making 7-(4-bromobutoxy)-3,4-dihydrocarbostyril TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2008-04-22 US disclosed
US-7361756-B2 Method of making 7-(4-bromobutoxy)-3,4-dihydrocarbostyril TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2008-04-22 US disclosed
WO-2007148191-A2 AN IMPROVED PROCESS FOR THE PREPARATION OF ARIPIPRAZOLE ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) 2007-12-27 WO disclosed
US-20060258869-A1 Process for the preparation of aripiprazole ALEMBIC LIMITED (IN) 2006-11-16 US disclosed
WO-2006001846-A1 METHOD OF MAKING 7-(4-BROMOBUTOXY)-3,4-DIHYDROCARBOSTYRIL TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2006-01-05 WO disclosed
WO-2006001846-A1 METHOD OF MAKING 7-(4-BROMOBUTOXY)-3,4-DIHYDROCARBOSTYRIL TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2006-01-05 WO disclosed
US-20050215585-A1 Method of making 7-(4-bromobutoxy)-3,4-dihydrocarbostyril TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2005-09-29 US disclosed
US-20050215585-A1 Method of making 7-(4-bromobutoxy)-3,4-dihydrocarbostyril TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2005-09-29 US disclosed
US-6514991-B2 Treating metabolic disorders mediated by insulin resistance or hyperglycemia; treating or inhibiting type 11 diabetes or urinary incontinence; increasing the lean meat to fat ratio in a mammal WYETH 2003-02-04 US disclosed
US-20020068751-A1 Phenyl-oxo-tetrahydroquinolin-3-yl beta-3 adrenergic receptor agonists AMERICAN HOME PRODUCTS CORPORATION 2002-06-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020068751-A1 Phenyl-oxo-tetrahydroquinolin-3-yl beta-3 adrenergic receptor agonists ADRB1, ADRB3, ADRB2 CRBN 3362/4885DDB1 2630/4885IKZF3 2888/4885
US-20060258869-A1 Process for the preparation of aripiprazole CYP2F1, CYP3A4, CYP2A7 CRBN 604/4885DDB1 3783/4885IKZF3 3491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.